Compare LPSN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPSN | LPCN |
|---|---|---|
| Founded | 1995 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 19.1M |
| IPO Year | 2000 | 2011 |
| Metric | LPSN | LPCN |
|---|---|---|
| Price | $1.86 | $2.14 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 64.2K | 33.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,838,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $1.81 |
| 52 Week High | $7.54 | $12.37 |
| Indicator | LPSN | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 39.89 |
| Support Level | $1.80 | $1.94 |
| Resistance Level | $2.44 | $2.50 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 90.22 | 13.95 |
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.